PRESS RELEASE
News
-
-
PRESS RELEASE
FSD Pharma, Inc. Wins Final Judgment to Confirm Arbitration Award of $3,059,998 Plus Interest Entered Against Dr. Raza Bokhari, Currently Serving as Chairman and CEO of Medicus Pharma Ltd.
FSD Pharma Inc. announces victory in legal battle against Dr. Raza Bokhari. Court judgment grants FSD Pharma damages and interest. Future plans detailed -
PRESS RELEASE
SouthGobi Announces Voting Results of Annual General Meeting; Appointment of Independent Non-Executive Director; Appointment of Lead Director; Change in Composition of Board Committees; And Dissolution of Operations Committee
SouthGobi Resources Ltd. announces voting results, appointment of directors, and dissolution of operations committee. Mr. Fan Keung Vic Choi elected as independent non-executive director -
PRESS RELEASE
Nagarro SE: Nagarro’s Annual General Meeting of June 27, 2024, passes all resolutions and appoints KPMG as auditor
Nagarro SE's Annual General Meeting on June 27, 2024, approves all resolutions and appoints KPMG as auditor. Details on the meeting outcomes and future dividend considerations -
-
-
PRESS RELEASE
EMA Committee For Medicinal Products For Human Use Adopts Positive Opinion Recommending Marketing Authorization Of Moderna’s RSV Vaccine, mRESVIA(R)
Moderna, Inc. receives positive opinion from EMA CHMP for mRESVIA mRNA-1345 vaccine for RSV in adults aged 60+. The decision from the European Commission is awaited -
PRESS RELEASE
VVV Resources Limited: Annual Report and Financial Statements for the year ended 31 December 2023
Press release by VVV Resources Limited announcing their Annual Report and Financial Statements for the year ended 31 December 2023. Details include operations and finance reviews, outlook, changes in the Board, and financial figures -
-
PRESS RELEASE
AB Science fait le point sur la demande d'autorisation de mise sur le marché conditionnelle du masitinib dans la SLA
AB Science annonce un avis négatif sur la demande de mise sur le marché du masitinib dans la SLA et prévoit un réexamen du dossier. Détails sur les raisons et les prochaines étapes
